Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116502 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL8071843 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL4733885 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL4735250 | 0.84 | PPM1B (0.43) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL4735247 | 0.84 | PPM1B (0.43) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL14424152 | 0.82 | PPM1B (0.35) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL14424095 | 0.81 | EPHX2 (0.39) | PPM1BPTPN1PPP1CC | |
| SCHEMBL14424084 | 0.81 | PPM1B (0.38) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 | |
| SCHEMBL14424106 | 0.81 | MEN1 (0.40) | PPM1BPTPN1PPP1CCSLC6A3TSHR | |
| SCHEMBL5400994 | 0.80 | SLC6A3 (0.50) | PPM1BPTPN1PPP1CCSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077809-A1 | PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | claimed |
| US-20080154043-A1 | PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | claimed |
| WO-2008077809-A1 | PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080154043-A1 | PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154043-A1 | PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES | CYP3A7, UGT2B7, CYP1B1 | PPM1B 3317/4885PTPN1 4567/4885PPP1CC 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.